Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. Sullivan RJ, et al. Among authors: flaherty k. Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15. Cancer Discov. 2018. PMID: 29247021 Clinical Trial.
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Atkins MB, et al. Among authors: flaherty kt. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s. doi: 10.1158/1078-0432.CCR-05-2560. Clin Cancer Res. 2006. PMID: 16609047
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Atkins MB, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s. doi: 10.1158/1078-0432.CCR-06-2231. Clin Cancer Res. 2007. PMID: 17255291 Review.
Inhibition of mutated, activated BRAF in metastatic melanoma.
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Flaherty KT, et al. N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011. N Engl J Med. 2010. PMID: 20818844 Free PMC article. Clinical Trial.
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. Bollag G, et al. Among authors: flaherty kt. Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454. Nature. 2010. PMID: 20823850 Free PMC article. Clinical Trial.
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. Johannessen CM, et al. Among authors: flaherty kt. Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24. Nature. 2010. PMID: 21107320 Free PMC article.
882 results